A detailed history of Captrust Financial Advisors transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 20,000 shares of AIM stock, worth $5,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,000
Previous 20,000 -0.0%
Holding current value
$5,000
Previous $9,000 22.22%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$0.32 - $0.77 $6,400 - $15,400
20,000 New
20,000 $8,000
Q2 2021

Aug 16, 2021

BUY
$1.93 - $2.39 $11,580 - $14,340
6,000 Added 42.86%
20,000 $43,000
Q1 2021

May 17, 2021

BUY
$1.88 - $2.82 $7,520 - $11,280
4,000 Added 40.0%
14,000 $32,000
Q4 2020

Feb 16, 2021

BUY
$1.68 - $2.45 $16,800 - $24,500
10,000 New
10,000 $18,000

Others Institutions Holding AIM

About AIM ImmunoTech Inc.


  • Ticker AIM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,049,300
  • Market Cap $12M
  • Description
  • AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...
More about AIM
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.